Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Paone, L. Lanata, P. Palermo, M. Bagnasco, S. Toti, F. Saibene, B. Moscatelli, A. Monguzzi, G. Puglisi (Rome, Milan, Italy). A prospective study of the effect of carbocysteine lysine salt on COPD exacerbations with or without inhaled steroids. Eur Respir J 2014; 44: Suppl. 58, 4667

Member's Comments

No comment yet.

Related content which might interest you: Effect of carbocysteine lysine salt on frequency of exacerbations in COPD patient treated with or without inhaled steroids Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Erdosteine oral treatment of hospitalised COPD exacerbation prolongs time to first re-exacerbation Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 The efficacy and safety of inhaled fluimucil-antibiotic-IT in the treatment of exacerbations of COPD and chronic bronchitis with bronchiectasis Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Effect of aclidinium bromide on exacerbations in patients with moderate-to-severe COPD: Pooled analysis of phase III studies Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids Source: International Congress 2016 – New findings in mucosal immunology Year: 2016 Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Treatment failure of hospitalized patients with COPD exacerbation using systemic corticosteroids plus antibiotics: Role of early inflammatory predictors Source: International Congress 2014 – Asthma and COPD management Year: 2014 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Effect of cromolyn inhaler on resistant neutrophilic cough variant of asthma, A phase two clinical trial Source: International Congress 2014 – Rationale behind respiratory drug development Year: 2014 QVA149 reduces the risk of moderate-to-severe exacerbations compared with open-label tiotropium in patients with severe COPD: The SPARK study Source: International Congress 2014 – Asthma and COPD management Year: 2014 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on exacerbations in moderate-to-severe COPD: Pooled analysis of two studies Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014 Impact of mucolytic treatment on COPD exacerbations Source: Annual Congress 2013 –Cell biology and murine models of asthma and inflammation Year: 2013 Safety of once-daily tiotropium and olodaterol fixed-dose combination via the respimat in chronic obstructive pulmonary disease in two 1-year studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 The adherence to inhaled drugs in COPD patients: Effect on survival Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 The effect of twice-daily aclidinium bromide on cough and sputum in patients with COPD: Results from phase III studies Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014